Crystalline forms
The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.
1. A crystalline form of zoledronic acid selected from the group consisting of:
a zoledronic acid L-carnitine hydrated complex,
a zoledronic acid L-carnitine complex,
a zoledronic acid, o-palmitoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-myristoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-lauroyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-decanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1.5), and
a zoledronic, L-carnitine, and water complex (1:1:1).
2. A crystalline form of zoledronic acid according to claim 1 selected from the group consisting of:
a zoledronic acid L-carnitine hydrated complex, characterized by a PXRD pattern having strong peaks at about 7.3, 12.6, 15.7, 17.8, 27.5±0.2 degrees two-theta;
a zoledronic acid L-carnitine complex, characterized by a PXRD pattern having peaks at about 8.8, 9.6, 13.2, 19.0, 30.4±0.2 degrees two-theta;
a zoledronic acid, o-palmitoyl-L-carnitine and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 6.8, 9.0, 13.5, 20.2, and 22.4±0.2 degrees two-theta;
a zoledronic acid, o-myristoyl-L-carnitine and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 9.6, 11.9, 14.3, 19.0, and 21.4±0.2 degrees two-theta;
a zoledronic acid, o-lauroyl-L-carnitine, and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 7.6, 14.1, 14.9, 20.8, and 23.1±0.2 degrees two-theta;
a zoledronic acid, o-decanoyl-L-carnitine, and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 5.5, 8.1, 13.3, 18.5, and 20.9±0.2 degrees two-theta;
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 3.25, 5.8, 11.3, 14.1, and 19.8±0.2 degrees two-theta;
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1.5), characterized by a PXRD pattern having strong peaks at about 3.3, 6.1, 14.0, 15.0, and 20.9±0.2 degrees two-theta; and
a zoledronic, L-carnitine, and water complex (1:1:1), characterized by a PXRD pattern having strong peaks at about 9.6, 10.0, 13.2, 18.9, 19.9±0.2 degrees two-theta.
3. A pharmaceutical formulation comprising a crystalline form of zoledronic acid selected from the group consisting of:
a zoledronic acid L-carnitine hydrated complex,
a zoledronic acid L-carnitine complex,
a zoledronic acid, o-palmitoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-myristoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-lauroyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-decanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1.5), and
a zoledronic, L-carnitine, and water complex (1:1:1) and at least one pharmaceutically acceptable carrier.
4. A pharmaceutical formulation according to claim 3 , wherein the pharmaceutical formulation is an oral formulation.
5. A method of treating osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, or Paget's disease or for adjuvant or neoadjuvant therapies comprising the step of:
administering to a patient in need thereof a therapeutically effective amount of a crystalline form of zoledronic acid according to claim 1 .
6. A method of treating osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, or Paget's disease or for adjuvant or neoadjuvant therapies comprising the step of:
administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation according to claim 3 .
7. A method according to claim 5 , wherein the administering step is oral administration.
8. A method according to claim 6 , wherein the administering step is oral administration.
9. A method for preparing a crystalline form of zoledronic acid selected from the group consisting of:
a zoledronic acid L-carnitine hydrated complex,
a zoledronic acid L-carnitine complex,
a zoledronic acid, o-palmitoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-myristoyl-L-carnitine and water complex (1:1:1),
a zoledronic acid, o-lauroyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-decanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1),
a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1.5), and
a zoledronic, L-carnitine, and water complex (1:1:1) comprising the steps of:
slurrying zoledronic acid and L-carnitine or a fatty acid derivative of L-carnitine in water, an organic solvent or a water-organic solvent mixture; or
grinding zoledronic acid and L-carnitine or a fatty acid derivative of L-carnitine in the presence of water, an organic solvent or a water-organic solvent mixture; and
evaporating the water, an organic solvent or a water-organic solvent mixture to form the crystalline form of zoledronic acid.
10. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid L-carnitine hydrated complex.
11. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid L-carnitine complex.
12. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-palmitoyl-L-carnitine, and water complex (1:1:1).
13. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-myristoyl-L-carnitine, and water complex (1:1:1).
14. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-lauroyl-L-carnitine, and water complex (1:1:1).
15. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-decanoyl-L-carnitine, and water complex (1:1:1).
16. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1).
17. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic acid, o-octanoyl-L-carnitine, and water complex (1:1:1.5).
18. A crystalline form of zoledronic acid according to claim 1 selected from a zoledronic, L-carnitine, and water complex (1:1:1).